Skip to content
10-Q

Quarterly Report

MABVAX THERAPEUTICS HOLDINGS, INC.

0001654954-18-011103

← back to feed
Filed
Oct 15, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2018 · Oct 11, 2018 9.25M sh
Capex Q1 2018 · Mar 31, 2018 $0
Capex Q1 2018 · Mar 31, 2017 $0
Long Term Debt Q1 2018 · Mar 31, 2018 $3.2M
Short Term Debt Q1 2018 · Mar 31, 2018 $2.54M
Cash And Equivalents Q1 2018 · Mar 31, 2018 $1.06M
Cash And Equivalents Q1 2018 · Dec 31, 2017 $885.71K
Cash And Equivalents Q1 2018 · Mar 31, 2017 $596.76K
Cash And Equivalents Q1 2018 · Dec 31, 2016 $3.98M
Stockholders Equity Q1 2018 · Mar 31, 2018 $834.3K
Stockholders Equity Q1 2018 · Dec 31, 2017 $1.13M
Current Liabilities Q1 2018 · Mar 31, 2018 $6.54M
Current Liabilities Q1 2018 · Dec 31, 2017 $5.81M
Total Liabilities Q1 2018 · Mar 31, 2018 $8.06M
Total Liabilities Q1 2018 · Dec 31, 2017 $7.66M
Current Assets Q1 2018 · Mar 31, 2018 $1.35M
Current Assets Q1 2018 · Dec 31, 2017 $1.21M
Total Assets Q1 2018 · Mar 31, 2018 $8.89M
Total Assets Q1 2018 · Dec 31, 2017 $8.79M
Sga Expense Q1 2018 · Mar 31, 2018 $1.8M
Sga Expense Q1 2018 · Mar 31, 2017 $2.27M
Rd Expense Q1 2018 · Mar 31, 2018 $1.63M
Rd Expense Q1 2018 · Mar 31, 2017 $2.82M
Net Income Q1 2018 · Mar 31, 2018 −$3.62M
Net Income Q1 2018 · Mar 31, 2017 −$5.35M
Operating Income Q1 2018 · Mar 31, 2018 −$3.43M
Operating Income Q1 2018 · Mar 31, 2017 −$5.09M
Revenue Q1 2018 · Mar 31, 2018 $0
Revenue Q1 2018 · Mar 31, 2017 $0